aflibercept + pranoprofen

Aflibercept + pranoprofen is a combination therapy used in ophthalmology, specifically studied for the treatment of choroidal neovascularization (CNV) in exudative age-related macular degeneration (AMD). Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF), thereby inhibiting abnormal blood vessel growth and leakage in the retina. Pranoprofen is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing inflammation. The combination involves intravitreal injection of aflibercept with adjunctive topical administration of 0.1% pranoprofen eye drops. Clinical studies suggest this combination may act synergistically to improve anatomical outcomes such as central retinal thickness and potentially reduce the number of required aflibercept injections, though no significant additional benefit on visual acuity over monotherapy has been demonstrated[1][2][3][4].

Other names

aflibercept plus pranoprofenIVA plus pranoprofen